Form D · Other Health Care
Akero Therapeutics, Inc.
South San Francisco, CA · CIK 0001744659
Offering snapshot reported Dec 18, 2018 · SEC filing
- Reported sold
- $45.5M Offering amount: $45.5M
- Investors reported
- 20 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Dec 10, 2018 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Dec 18, 2018 | Initial | $45,499,989 | No comparison | 20 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-328356
Source: Form D, filed Dec 18, 2018. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Kevin Bitterman | Director |
| Andrew Cheng | Director, Executive |
| Mark Iwicki | Director |
| Aaron Kantoff | Director |
| Aaron Royston | Director |
| Graham Walmsley | Director |
| Jonathan Young | Executive |
Issuer details
Industry: Other Health Care (See others in industry)
Address:
70 Harbor Way, 3rd Floor
South San Francisco, CA, 94080
South San Francisco, CA, 94080